Positive Antinuclear Antibody and Blaschkoid Lichen Planus Pigmentosus

Amal AlBalbeesi 1, 2

1. Dermatology, King Saud University College of Medicine, Riyadh, SAU
2. Dermatology, King Khalid University Hospital, Riyadh, SAU

Corresponding author: Amal AlBalbeesi, amalbalbeesi@gmail.com

Abstract

Lichen planus pigmentosus is a rare variant of lichen planus. It is an acquired pigmentary disorder of unknown etiology. It is characterized by dark brown and slate gray macules and patches. The nails, scalp, and oral mucosa are usually spared, unlike lichen planus. Lichen planus pigmentosus commonly involves the head and neck region as well as intertriginous areas such as the axillae, inframammary and inguinal regions. It can be associated with autoimmune diseases, endocrinopathies, and other variants of lichen planus such as fibrosing alopecia of the scalp. Variable clinical patterns of lichen planus pigmentosus including zosteriform, linear, and segmental had been published. Histopathologically, it is characterized by hyperkeratosis of the epidermis, hypergranulosis, variable degrees of lichenoid infiltration depending on the age of the lesion, and prominent melanin incontinence. Recent updates on erythema dyschromicum perstans that were considered similar to lichen planus pigmentosus, concluded that they could be differentiated on clinical bases as well as histopathology. Epidermal hyperkeratosis, hypergranulosis, apoptotic cells, lichenoid dermatitis, periappendageal infiltrate, and fibrosis with marked superficial dermal melanin incontinence aid to differentiate lichen planus pigmentosus from erythema dyschromicum perstans. During embryogenesis, cells migrate and follow developmental lines named after Blaschko, a German dermatologist, who first noted them. Blaschko’s lines (BL), do not follow neural, vascular, or lymphatic pathways. They appear as V-shaped on the back, S-shape on the abdomen, and linearly on limbs. We report a case of lichen planus pigmentosus over BL that is a rare presentation of the disease and associated positive antinuclear antibody (ANA) without overt manifestations of any connective tissue disease.

Categories: Dermatology, Allergy/Immunology, Rheumatology

Keywords: connective tissue diseases, antinuclear antibody, lichen planus, ashy dermatosis, blaschko lines, lichen planus pigmentosus

Introduction

In 1956, Shima was the first to describe lichen planus pigmentosus, and was considered to be a variant of lichen planus. It involves most commonly the face, trunk, and extremities [1]. Infrequently the intertriginous areas are involved. However, antinuclear antibody (ANA) was reported to be positive by indirect immunofluorescence using rat esophagus, in mucosal erosive lichen planus, in 40.42% of patients [2]. Blaschko’s lines (BL) were named after Alfred Blaschko, a German dermatologist in 1858-1922 [3,4]. They do not follow neural, vascular, or lymphatic pathways. The cell migration appears as V-shape on the back, S-shape on the abdomen anteriorly, and as linear lines on the extremities. Congenital and acquired dermatosis have been reported to present over these lines. Linear nevus sebaceous, incontinentia pigmenti, epidermal nevus, and focal dermal hypoplasia (Goltz syndrome) are among the congenital diseases that follow BL [5]. Lichen striatus, lichen planus, pсорiasis, atopic dermatitis, graft versus host disease, lupus erythematosus, adult blaschkitis, and lichen nitidus could follow BL [6].

Case Presentation

A 30-year-old female presented to the dermatology clinic with asymptomatic pigmentation over the right side of the trunk for one year following C section for abruptio placenta at 28 weeks, not preceded by erythema. The lesions started on the breast and then spread to involve the chest and abdomen sparing both axillae and face. The patient complained of knee joint pains and oral ulcers prior to the eruption but there was no history of photosensitivity or malar erythema. Also, there was no significant past medical history including autoimmune diseases, drug ingestion, or topical application.

On examination, she had non-scaly multiple confluent and reticulated violaceous-brown blotchy macules and lines over breast and trunk that sharply respected the midline following BL (Figures 1-3).
FIGURE 1: Unilateral violaceous and brown macules forming lines over trunk respecting the midline
FIGURE 2: Brown and violaceous macules around breast and areola
The face, neck, underarms, nails, and mucous membranes were spared. There were no discoid lupus erythematosus (DLE) lesions over the head and neck region. Mucous membrane examination showed gingivitis; however, no ulcers or any oral lesions were seen.

Complete blood count, erythrocyte sedimentation rate (ESR), liver and kidney functions, fasting blood sugar, and thyroid function tests including thyroid-stimulating hormone (TSH) and thyroxine (T4) were all normal.

Hepatitis screening including B and C were negative. ANA titer was 1:1280. However, double-stranded deoxyribonucleic acid (Ds DNA), antiSmith, antiphospholipid antibodies, lupus anticoagulant, Sjogren’s syndrome A autoantibody (SS-A) and Sjogren’s syndrome B autoantibody (SS-B), anti-smooth muscle antibody (ASMA), were all negative. Elevated ANA titer is recognized in rheumatological and non-rheumatological diseases including Hashimoto’s thyroiditis and autoimmune hepatitis as well as in the normal population. Based on the normal liver function test (LFT), negative ASMA, and normal thyroid function, the diagnosis of autoimmune hepatitis and thyroid diseases were excluded.

Histopathological examination of a skin punch biopsy showed basket weave stratum corneum, atrophic epidermis, small foci of lymphocytic exocytosis but no necrotic keratinocytes or vacuolar changes. In the dermis, there was pigment incontinence, perifollicular lymphohistocytic infiltrate, fibrosis, and mild perivascular lymphohistocytic infiltrate (Figures 4 to 7).
Colloidal iron stain showed mucin limited to the papillary dermis, however, no basement membrane thickening. Unfortunately, perilesional Direct Immunofluorescence (DIF) was not performed. Based on clinicopathological correlation the diagnosis of old lichen planus pigmentosus following BL was made. Treatment with tacrolimus 0.1% and mometasone resulted in minimal improvement of pigmentation.

**Discussion**

Lichen planus pigmentosus commonly affects Indians, Asians, and Middle Eastern populations [1]. It presents as slate grey to dark brown pigmented macules involving mainly the head and neck or the trunk, flexures, and extremities [7]. Lichen planus pigmentosus can follow linear, zosteriform, segmental, and rarely blashkoid patterns and had been reported as early as 10 years of age [8-11].
Here we present a case of lichen planus pigmentosus following BL with positive ANA as a solitary immunological finding and no clinical evidence of connective tissue disease or any other autoimmune non-rheumatological diseases. Lichen planus and lupus erythematosus (LE) have been infrequently reported in the same patient and have been called the lichen planus-lupus erythematosus overlap [7]. This presentation is unique in several aspects including the distribution of lesions over BL that is rarely encountered, and the immunological association with positive ANA, and lack of any evidence of lupus in the current time of presentation. Having the lesions following abruptio placenta may have triggered an immunological reaction and resulted in this peculiar presentation. Of interest, lichen planus has been reported with pregnancy [8,12].

Differential diagnosis of this presentation includes post-inflammatory hyperpigmentation (PIH) and ashy dermatosis [13]. Usually, the absence of any history of preceding erythema rules out PIH. Commonly ashy dermatosis presents with former lacking erythematous border. Lichen planus pigmentosus and ashy dermatosis are considered two different diseases based on the clinical presentation [15,14]. The findings of hyperkeratosis, hyper granulosis, licheniform infiltrate, perifollicular infiltrate and fibrosis, and superficial dermal pigment incontinence favor the diagnosis of lichen planus pigmentosus. Vacularization of basal cells was more common in ashy dermatosis as reported by Rutnin et al. [15].

Based on history and histopathological findings in our patient, the diagnosis of lichen planus pigmentosus was confirmed and the diagnosis of ashy dermatosis and lupus was ruled out.

Usually, lichen planus pigmentosus runs a longer course than the other variants of lichen planus. Successful treatment has been achieved using topical steroids and tacrolimus ointment but with poor response to chloroquine [14]. Small dose isotretinoin and sunscreens showed promising results in controlling the disease progression and extent of pigmentation [15]. Other treatment modalities such as colchicine, dapsone, and mycophenolate mofetil were unsuccessful [15]. Tranexamic acid is one of the modalities that could be used with variable outcomes [16]. Low-fluence Q-switched Nd-YAG (1064 nm) combined with 0.1% tacrolimus, was reported to clear facial pigmentation [17].

Conclusions

In conclusion, lichen planus pigmentosus in blaschkoid pattern had been rarely reported. According to the timely review of the literature, few cases had been reported so far, and hence the significance of such a case to be added to the current literature. On the other hand, the appearance of the lesions after abruptio placenta stands as a peculiar concurrent event with such a presentation. This event may have triggered the immune response against mosaic keratinocytes and the finding of positive ANA. Follow-up of such cases is required to rule out the progression to systemic lupus or any other connective tissue disease.

Additional Information

Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Shima T: Lichen planus pigmentosus. Jpn J Dermatol. 1956, 66:54-53.
2. Carrizosa AM, Elorza FL, Camacho FM: Antinuclear antibodies in patients with lichen planus. Exp Dermatol. 1997, 6:54-6. 10.1111/j.1600-0625.1997.tb00146.x
3. Moss C, Larkins S, Stacey M, Blight A, Farrndon PA, Davison EV: Epidermal mosaicism and Blaschko’s lines. J Med Genet. 1995, 30:752-5. 10.1136/jmg.30.9.752
4. Suárez-Peñaranda M, Figueroa O, Rodriguez–Blanco I, Aliste C, Casas L: Unusual interface dermatoses distributed along Blaschko’s lines in adult patients. Am J Dermatopathol. 2017, 39:144-9. 10.1097/DAD.0000000000000689
5. Müller CS, Schmalzt R, Vogt T, Pfühler C: Lichen striatus and blaschkitis: reappraisal of the concept of blaschkolinear dermatoses. Br J Dermatol. 2011, 164:257-62. 10.1111/j.1365-2133.2010.10053.x
6. Vibhu M, Sarita S, Ram C: Lichen planus pigmentosus: a clinic-o-etiological study. Indian Dermatol Online J. 2019, 10:288-292. 10.4103/idoj.IDOJ_253_18
7. Droubi MS, Pitsilidou MR: Lichen planus. Fitzpatrick’s Dermatology in General Medicine. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K (ed); McGraw-Hill Inc, New York; 1999.
8. Kumar S, Okade R, Rahman YA: Lichen planus pigmentosus: a clinico-etiological study. Indian Dermatol Online J. 2016, 16:e383-4. 10.18295/squmj.2016.16.03.024
9. Alonso-Corral MJ, Garrido-Colmenero C, Almodovar-Real A, Ruiz-Villaverde R: Lichen planus pigmentosus with blaschkoid distribution. Sultan Qaboos Univ Med J. 2016, 16:e383-4. 10.18295/squmj.2016.16.03.024
10. Polat M, Tuman B, Özyalvaş G: A case of unilateral blaschkoid lichen planus pigmentosus. An Bras
11. Rai T, Bohara A, Kumar Jha P: A case of lichen planus pigmentosus in blaschkoid pattern in a 10-year-old female. Clin Dermatol Rev. 2021, 5:1:104–106. 10.4103/CDR.CDR_42_19

12. Barros HR, Almeida JRP, Dinato SLM, Sementilli A, Romiti N: Lichen planus pigmentosus inversus. An Bras Dermatol. 2013, 88:146–149.

13. Rutnin S, Udompianich S, Pratumchart N, Harnchoowong S, Vachiramon V: Ashy dermatosis and lichen planus pigmentosus: the histopathological differences. Biomed Res Int. 2019, 2019:5829185. 10.1155/2019/5829185

14. Rieder E, Kaplan J, Kamino H, Sanchez M, Pomeranz MK: Lichen planus pigmentosus. Dermatol Online J. 2013, 19:20713.

15. Muthu SK, Narang T, Saikia UN, Kanwar AJ, Parsad D, Dogra S: Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study. Int J Dermatol. 2016, 55:1048–54. 10.1111/ijd.13295

16. Zenjari L, Elfetoiki FZ, Hali F, Skalli H, Chiheb S: Oral tranexamic acid in the treatment of lichen planus pigmentosus: a prospective study of 20 cases [Article in French]. Ann Dermatol Venereol. 2020, 147:818–22. 10.1016/j.annder.2020.06.017

17. Mathews I, Thappa DM, Singh N, Gochhait D: Lichen planus pigmentosus: a short review. Pigment Int. 2016, 3:5–10. 10.4103/2349-5847.184265